Search for: "ASTRAZENECA LP" Results 61 - 80 of 157
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Feb 2009, 9:35 pm
AstraZeneca Pharmaceuticals LP, No. 6:07-cv-15733-Orl-22DAB, slip op. [read post]
11 Dec 2011, 9:00 pm by Stephanie Figueroa
AstraZeneca Pharmaceuticals LP, the Federal Circuit explained when a secret invention can be considered "made" (or conceived and reduced to practice) so that it can be used as prior art against a patent. [read post]
11 Dec 2011, 9:00 pm by Stephanie Figueroa
AstraZeneca Pharmaceuticals LP, the Federal Circuit explained when a secret invention can be considered "made" (or conceived and reduced to practice) so that it can be used as prior art against a patent. [read post]
15 Apr 2016, 8:26 am by Tom Lamb
These medications are available by prescription and over-the-counter (OTC) from various pharmaceutical companies, for example: PRILOSEC (omeprazole magnesium) | prescription drug | AstraZeneca LPPRILOSEC OTC (omeprazole magnesium) | over-the-counter | Procter & Gamble Manufacturing Co.PREVACID (lansoprazole) | prescription drug | Takeda Pharmaceuticals America, Inc.PREVACID 24 HR (lansoprazole) | over-the-counter | Novartis Consumer Health, Inc.NEXIUM (esomeprazole magnesium) |… [read post]
19 Oct 2023, 4:00 am by Howard Friedman
AstraZeneca Pharmaceuticals LP, (D MD, Oct. 17, 2023), a Maryland federal district court dismissed a Title VII religious discrimination claim by two employees who were denied a religious exemption from a company's Covid vaccine mandate, finding that their objections were not religious in nature. [read post]
29 Aug 2016, 12:30 pm by Tom Lamb
For use as an example, here is the relevant part of an August 17, 2016 FDA Supplemental Approval letter to AstraZeneca Pharmaceuticals LP for Farxiga: Please refer to your supplemental New Drug Application (sNDA) dated and received July 28 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Farxiga (dapagliflozin) tablets. [read post]
27 Feb 2015, 5:02 am by Mary Jane Wilmoth
AstraZeneca to Pay $7.9 Million to Resolve Kickback Allegations AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act. [read post]
3 Oct 2010, 8:57 pm by Patent Docs
Astrazeneca Pharmaceuticals LP... [read post]
26 Mar 2012, 1:43 am by FDABlog HPM
District Court for the District of Columbia denied AstraZeneca Pharmaceuticals LP’s (“AstraZeneca’s”) Application for Prelimiary Injunction and dismissed without prejudice the action AstraZeneca filed on March 12, 2012 seeking to enjoing FDA from granting final ANDA approval for a generic version of the company’s blockbuster antipsychotic drug SEROQUEL (quetiapine fumarate) Tablets (NDA No. 020639) as early as March 26, 2012 (as well… [read post]
23 Sep 2009, 10:02 pm
AstraZeneca Pharmaceuticals LP, No. 08-1056 (1st Cir. [read post]
25 May 2012, 11:32 am by Robert Vrana
  Judge Stark cited the Federal Circuit’s recent decision in AstraZeneca Pharmaceuticals LP v. [read post]
9 Jul 2012, 7:41 pm by FDABlog HPM
Karst –  In a decision that, unless appealed, marks the end of AstraZeneca Pharmaceuticals LP’s (“AstraZeneca’s”) battle with FDA over the approval of generic versions of the company’s blockbuster antipsychotic drug SEROQUEL (quetiapine fumarate) Tablets, the U.S. [read post]
3 Nov 2010, 5:56 am by The Docket Navigator
Astrazeneca Pharmaceuticals LP, et. al., 2-08-cv-04786 (PAED October 20, 2010, Memorandum and/or Opinion) (Yohn, J.) [read post]